News and Trends 18 Aug 2016
Invidior approaches FDA Approval of Opioid Addiction Treatment
Invidior has revamped buprenorphine with a sustained release formulation known as RBP-6000 that shows promising results in Phase III clinical trials for the treatment of opioid addiction. The latest addiction treatment from Invidior, RBP-6000, has made considerable progress through Phase III clinical trials. At the core of RBP-6000 is the old drug, buprenorphine, but Invidior has […]